Determinants of pharmaceutical expenditures of urban households
A time series study in Kermanshah province (Iran)
Keywords:
pharmaceutical expenditures, price elasticity, income elasticity, urban households, Kermanshah ProvinceAbstract
Introduction: In recent decades, the development of medical and pharmaceutical science has led to a heavy financial burden on the government, insurance companies, and the general population. Due to the increasing the cost of pharmaceutical products in the Kermanshah Province, policy makers have tried to identify the factors that resulted in the increases. The aim of this study was to determine the main factors that affect the expenditures for pharmaceutical products by urban households in Kermanshah Province, Iran.
Methods: This analytical-descriptive study was conducted using time series method. The study population was urban households of Kermanshah Province from 1991 to 2013. The explanatory variables of the log-log model were drug price index (LnDPI), the average income of urban households (LnINC), the number of physicians per 1,000 people (LnPH), and the number of hospital beds per 1,000 people (LnBE).The required data were acquired from the Statistical Center of the Ministry of Health and Medical Education. The unit root was evaluated by the Dickey-Fuller test. Stata v.11 software was used for the statistical analysis.
Results: Coefficients of LnDPI and LnPH were 0.97 and 0.77, respectively, and they were statistically significant (p < 0.05). Also, the coefficients of D. LnINC (first difference of LnINC) and LnBE were 0.34 and 1.8, respectively, and both of them were statistically insignificant (p > 0.05).
Conclusion: The results showed that drugs are non-elastic and essential for households. It should be noted that the health policy makers in Iran should conduct appropriate planning to ensure both the physical and financial accessibility to drugs by urban households. The development of basic and supplementary health insurance coverage, especially for poor populations and urban areas where there are patients with chronic diseases, can be a suitable solution to reduce barriers to acquiring the required drugs.
References
Jahangiri G. Estimating the demand for drugs in the Iranian economy (MSc thesis). Tehran University;
(Persian).
Ghanati E, Hadiyan M , Daghighi AR. Economic expenditures of multiple sclerosis medications and
feasibility of providing health insurance policies for medications. Journal of Health Administration. 2011;
(45): 37-54. Available from: http://jha.iums.ac.ir/browse.php?mag_id=45&slc_lang=en&sid=1.
Javidannezhad S. Drug information. Printing and Publication Institute of Tehran University, 1st ed, 1991.
(Persian)
Amani F, Shaker A. Patterns of drug use among urban households in Ardabil. Payavard Salamat, ISSN:
-2665. 2011; 5(5): 33-41 .Available from: http://payavard.tums.ac.ir/search.php?slc_lang=en&sid=1.
Baldini CG, Culley EJ. Estimated cost savings associated with the transfer of office-administered specialty
pharmaceuticals to a specialty pharmacy provider in a Medical Injectable Drug program. J Manag Care
Pharm. 2010; 17(1): 51-9, PMID: 21204590.
Kebriaeezadeh A, Koopaei NN, Abdollahiasl A, Nikfar S, Mohamadi N. Trend analysis of the
pharmaceutical market in Iran; 1997–2010; policy implications for developing countries. Daru J Pharm Sci.
; 21: 52. doi: 10.1186/2008-2231-21-52, PMID: 23805853, PMCID: PMC3718624.
Golestani M, Rasekh H, Imani A. The relationship between pharmaceutical expenditures, health care
expenditures and gross domestic product in Iran: 1999-2008. Pharmaceutical Sciences. 2012; 18(1): 9-17.
Islamic Parliament Research Center of Iran, The study of the pharmaceutical industry after the Islamic
Revolution of Iran. 2006. Available from: http://rc.majlis.ir/fa/report/show/733366.
Homaie Rad E, Vahedi S, Teimourizad A, Esmaeilzadeh F, Hadian M, Torabi Pour A. Comparison of the
effects of public and private health expenditures on the health status: a panel data analysis in eastern
mediterranean countries. Int J Health Policy Manag. 2014; 1(2): 163-7. doi: 10.15171/ijhpm.2013.29,
PMID: 24596857, PMCID: PMC3937925.
Baily MN. Research and development costs and returns: the US pharmaceutical industry. J Polit Econ.
; 80: 70-85. Available from: http://www.jstor.org/stable/1830132?seq=1#page_scan_tab_contents. doi:
/10.1086/259862
Blazer DG, Wu L-T. The epidemiology of at-risk and binge drinking among middle-aged and elderly
community adults: National Survey on Drug Use and Health. Am J Psychiatry.2009; 166 (10): 1162-9. doi:
1176/appi.ajp.2009.09010016, PMID: 19687131.
Emamgholipour Sefiddashti S, Rashidian A, Nakhaee M. Estimation of Medication Demand Function in
Iranian Households using Panel Data, 2004-2011. Hakim Research Journal. 2014; 17(3): 235-41. Available
from: http://www.hakim.hbi.ir/browse.php?a_id=1369&sid=1&slc_lang=en
Ravangard R, Jafari A, Motlagh SN. Drug demand function for Iranian urban households based on
households' budget. Health Scope. 2014; 3(3): 18494.
Rahbar A, Barouni M, Bahrami M, Saber Mahani A. Estimation of Drug Demand Function in Iranian
Urban Population through Household Budget, 1990-2011. Toloo-e-behdasht. 2013; 12(3):44-58. Available
from: http://tbj.ssu.ac.ir/browse.php?a_code=A-10-422-1&slc_lang=en&sid=1&sw=Health.
EbadifardAzar F, Rezapoor A, Rahbar A, Hosseini Shokouh SM. Estimation of the Function of Medicine
Demand in Islamic Republic of Iran. J Mil Med. 2013; 15(2): 163-8.
Samadi A, Homaie Rad E. Determinants of Healthcare Expenditure in Economic Cooperation Organization
(ECO) Countries: Evidence from Panel Cointegration Tests. Int J Health Policy Manag. 2014; 1(1): 63-8.
doi: 10.15171/ijhpm.2013.10, PMID: 24596838, PMCID: PMC3937933.
Abolhalaj M, Bastani P, Ramezanian M, Tamizkar N. Production and consumption financial Process of
drugs in Iranian healthcare market. Develop Countr Stud. 2013; 3(1): 187-91. Available from:
http://www.iiste.org/Journals/index.php/DCS/article/view/3898.
Radyowijati A, Haak H. Improving antibiotic use in low-income countries: an overview of evidence on
determinants. SOC SCI MED. 2003; 57(4): 733-44. doi: 10.1016/S0277-9536(02)00422-7.
Nouraei Motlagh S, Rezapour A, Lotfi F, Safari H, Hadian M. Factors Influencing Pharmaceutical Demand
in Iran: Results from a Regression Study. International Journal of Hospital Research. 2014; 3(2): 93-6.
Available from:
Verbeek M. A guide to modern econometrics, 4th ed. John Wiley & Sons 2012. ISBN: 978-1-119-95167-4.
Smith DG. The effects of copayments and generic substitution on the use and costs of prescription drugs.
Inquiry. 1993: 189-98, PMID: 8314607.
Contoyannis P, Hurley J, Grootendorst P, Jeon SH, Tamblyn R. Estimating the price elasticity of
expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from
Quebec, Canada. Health Econ. 2005; 14(9): 909-23. doi: 10.1002/hec.1041, PMID: 16127675.
Shea DG, Terza JV, Stuart BC, Briesacher B. estimating the effects of prescription drug coverage for
Medicare beneficiaries. Health Serv Res. 2007; 42(3): 933-49, PMID: 17489897, PMCID: PMC1955253.
McPake B, Banda EEN. Contracting out of health Services in developing countries. Health Policy Plan.
; 9(1): 25-30. doi: 10.1093/heapol/9.1.25, PMID: 10133098.
WHO/DAP. Competitive mechanisms for public drug supply: options, issues, and cautions (working draft).
Geneva: World Health Organization; 1997.
Folland S, Goodman AC, Stano M. The economics of health and health care, 5th ed. Pearson Prentice Hall
New Jersey, 2007. ISBN-0-13-227942-8, PMCID: PMC2375556.
Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for
brand-name drugs: medical expenditure panel survey, 1997–2000. Ann Intern Med. 2005; 142(11): 891-7.
doi: 10.7326/0003-4819-142-11-200506070-00006, PMID: 15941695.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
